SAVE MONEY ON TRAVEL DEALS

Tamoxifen is a widely used and effective drug designed to treat breast cancer. But the scientists said resistance to tamoxifen is problematic in recurrent disease that affects 25 percent to 35 percent of patients because therapy resistant metastatic tumor cells are a major cause of death.

In the new study, Arzu Umar of the Erasmus University Medical Center and colleagues in the Netherlands and Washington examined thousands of tumor cells taken from 51 tamoxifen therapy-sensitive and therapy-resistant tumors. Using a combination of proteomic and mass-spectrometry approaches they identified a set of 100 proteins expressed at different abundance levels in the two tumor groups, highlighting a potential profile for tamoxifen resistance.

While further work with additional samples will be needed, the researchers said the profile could be clinically useful, especially considering their approach used minute amounts of tissue samples, making it applicable at even the earliest tumor stages.

The research is detailed in the journal Molecular and Cellular Proteomics.

 BREAKING STORIES

Handgrip may predict disability risk

Compromised family better than institution

Parents see their children skinnier

Icesave dispute focus of Europe meeting

Early menopause linked to earlier dementia

9 dead in Belgium building collapse

EIB loans SATA Group $53 million

Dutch teen sailor found

Netherlands to kill 35,000 goats

Quitting smoking can reverse asthma damage

Taylor: Taiwan, Libya backed campaign

Police: Man blackmailed teens' parents

Artificial meat grown in laboratory

Conscious man diagnosed in coma for years

Worm targets Dutch bank iPhone app

Movie subtitles improve foreign speech

'Too realistic' riot exercise called off

Boat tails on trucks save fuel

ESA seeks hypergravity experiments

Court crushes solo sailor's record hopes